Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRaw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Finished Goods: 2023-2024

Historic Finished Goods for Tg Therapeutics (TGTX) over the last 2 years, with Dec 2024 value amounting to $13.9 million.

  • Tg Therapeutics' Finished Goods rose 164.86% to $21.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.1 million, marking a year-over-year increase of 164.86%. This contributed to the annual value of $13.9 million for FY2024, which is 597.25% up from last year.
  • Tg Therapeutics' Finished Goods amounted to $13.9 million in FY2024, which was up 597.25% from $2.0 million recorded in FY2023.
  • Over the past 5 years, Tg Therapeutics' Finished Goods peaked at $13.9 million during FY2024, and registered a low of $2.0 million during FY2023.
  • Moreover, its 2-year median value for Finished Goods was $8.0 million (2023), whereas its average is $8.0 million.
  • Data for Tg Therapeutics' Finished Goods shows a peak YoY surged of 597.25% (in 2024) over the last 5 years.
  • Over the past 2 years, Tg Therapeutics' Finished Goods (Yearly) stood at $2.0 million in 2023, then surged by 597.25% to $13.9 million in 2024.